Even though, for the above-mentioned reasons, the current ligands cannot be used in the clinic, our results suggest further development of more selective NR1D1-activating drugs, which could be of interest in the treatment of myopathies and likely other muscle disorders characterized by altered Ca2+ homeostasis. This evidence concerns the gene NR1D1 and muscular disease.